Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Nkarta (NKTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB) and Nkarta (NKTX).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen (BIIB)
In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Biogen, with a price target of $197.00. The company’s shares closed last Wednesday at $180.54.
According to TipRanks.com, Zemansky is a 5-star analyst with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $206.61, a 15.2% upside from current levels. In a report issued on April 10, Morgan Stanley also maintained a Hold rating on the stock with a $200.00 price target.
See today’s best-performing stocks on TipRanks >>
Nkarta (NKTX)
In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Nkarta, with a price target of $16.00. The company’s shares closed last Wednesday at $2.42, close to its 52-week low of $1.31.
According to TipRanks.com, Bodnar is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nkarta with a $12.50 average price target, implying a 445.9% upside from current levels. In a report issued on March 31, Mizuho Securities also maintained a Buy rating on the stock with a $12.00 price target.
Read More on BIIB:
